Dupilumab, a fully human mAb inhibiting signaling of both interleukin IL-4 and IL-13, is labeled for the treatment of moderate-severe AD in adults and adolescents (Ferrucci et al., 2022; Stingeni et al., 2022). The gene discussed is IL4; the disease is Alzheimer disease.